CTCBIO Inc.
Financials
Valuation Metrics
CTCBIO Inc.'s Market Cap is ₩636B. At end of 2025 it was ₩1118B. Ranked #1550 of 2,405 in KR market (top 64%), #904 of 1,627 on KOSDAQ (top 56%), #170 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 63.60B KRW | KR#1,550/2,405 Sec#170/231 |
| Revenue | 122.38B KRW | KR#1,301/2,405 Sec#81/231 |
| Net Income | 7.51B KRW | KR#1,063/2,405 Sec#67/231 |
| Total Assets | 143.24B KRW | KR#1,540/2,405 Sec#117/231 |
| Net Assets | 72.72B KRW | KR#1,648/2,405 Sec#136/231 |
| Employees | 257 | KR#909/2,405 Sec#76/231 |
| Value | ||
| P/E | 8.46x | KR#750/2,405 Sec#38/231 |
| P/B | 0.87x | KR#1,423/2,405 Sec#88/231 |
| P/S | 0.52x | KR#1,000/2,405 Sec#50/231 |
| EV/EBITDA | 7.21x | KR#449/2,405 Sec#20/231 |
| FCF Yield | 5.66% | KR#846/2,405 Sec#44/231 |
| Profitability | ||
| ROE | 10.33% | KR#587/2,405 Sec#40/231 |
| ROA | 5.25% | KR#706/2,405 Sec#59/231 |
| Op. Margin | 9.36% | KR#567/2,405 Sec#48/231 |
| Revenue Growth | -16.13% | KR#2,058/2,405 Sec#187/231 |
| Financial Health | ||
| Debt Ratio | 96.96% | KR#1,522/2,405 Sec#173/231 |
| Total Debt | 35.70B KRW | KR#1,139/2,405 Sec#83/231 |
| FCF | 3.60B KRW | KR#984/2,405 Sec#70/231 |
| Cash | 16.75B KRW | KR#1,366/2,405 Sec#108/231 |
| Current Ratio | 1.56x | KR#1,140/2,405 Sec#124/231 |
| Net Debt/EBITDA | 1.65x | KR#805/2,405 Sec#56/231 |
| Performance | ||
| 1Y Return | -48.93% | KR#1,910/2,405 Sec#162/231 |
| 1M Return | -14.89% | KR#1,573/2,405 Sec#159/231 |
| From 52W High | -53.12% | KR#1,310/2,405 Sec#104/231 |
| 1Y MDD | -53.00% | KR#1,083/2,405 Sec#90/231 |
| Trading | ||
| Volume | 18,390 shares | KR#1,536/2,405 Sec#148/231 |
| Trading Value | 47.7M KRW | KR#1,746/2,405 Sec#185/231 |
| Foreign Own. | 1.79% | KR#1,701/2,405 Sec#164/231 |
| Per Share | ||
| EPS | 311 KRW | KR#1,159/2,405 Sec#80/231 |
| BPS | 3,007 KRW | KR#1,870/2,405 Sec#142/231 |
Company Info
CTC BIO, established in 1995 and headquartered in Hwaseong-si, Gyeonggi-do, listed on KOSDAQ in 2002. The company researches, develops, manufactures, and distributes animal pharmaceuticals, including feed additives, injectables, and vaccines, as well as improved new drugs and generic drugs. CTC BIO possesses 5 domestic production bases, 2 research institutes, and operates local subsidiaries in the USA and Indonesia, expanding its production base by acquiring the Ansan factory from SK Chemicals in 2014. Its technological prowess is recognized through core technologies such as microbial fermentation and drug coating, alongside the development of innovative film-type and complex formulations.